Updated
Updated · CNBC · Sep 1Novartis Shares Jump 4% After MS Drug Remibrutinib Cuts Relapse Rates
3 articles · Updated · CNBC · Sep 1Summary
- Novartis rose 4% in premarket trading after reporting positive trial data for remibrutinib in multiple sclerosis.
- Remibrutinib significantly reduced relapse rates versus another treatment, giving investors a clear catalyst for the stock move.
- The gain stood out in a mixed premarket session that saw chipmakers fall more than 1% as Treasury yields rose, while energy stocks climbed with oil.
Insights
With tech stocks plunging and options markets flashing red, is this the beginning of a devastating crash for the semiconductor industry? Will a language app's aggressive strategy truly mirror Netflix's legendary turnaround, or is this massive valuation an overhyped illusion? Could Robinhood's unexpected leap into Ethereum blockchain technology completely redefine the future landscape of retail investing?